Dr Terri Cooper is a member of the Investment Committee and the Nominations Committee. Terri is a recognised life sciences healthcare expert, with more than 35 years’ experience working globally across public and private sectors with complex industry, business, technology, DEI, brand-building and regulatory imperatives. This includes leading Deloitte’s global healthcare sector and building the firm’s Life Sciences R&D practice. Terri is the board chair for Verso Biosense, the vice board chair for the Classical Theatre of Harlem and sits on the advisory boards of the USTA Foundation and EnrichedHQ. She holds a PhD in pharmacology from the University of London.
Dr Terri Cooper
Latest news
-
LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases
Read more: LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases -
First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Read more: First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases -
New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
Read more: New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya